Literature DB >> 15018855

Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues.

Lee-Wen Huang1, Shiouh-Lirng Chao, Pei-Hsin Chen, Hui-Ping Chou.   

Abstract

BACKGROUND: Human papillomaviruses (HPV) have been considered to be the necessary and central agents of cervical carcinoma.
OBJECTIVE: The aim of this study was to determine the prevalence and genotypes of HPV in archival cervical carcinomas. STUDY
DESIGN: The study included 152 paraffin-embedded, formaldehyde-fixed cervical carcinoma specimens. To improve the detection and typing of HPV in archival tissues, we conducted a comprehensive study in which, polymerase chain reaction (PCR)-based methods using E7 type-specific (TS) and L1 modified general primers (MY11/GP6+ and GP5+/GP6+) were employed.
RESULTS: Overall HPV prevalence was 98% in the cervical carcinomas. HPV 16 was detected in 66% of the tumors, HPV 18 in 22%, HPV 31 in 13%, HPV 33 in 9%, and HPV 58 in 9%. Notably, multiple HPV types were present in 44 (28.9%) of the 152 cervical carcinomas. The most common co-infections were HPV types 16/18 (12 cases), followed by HPV types 16/31 (7 cases). Additionally, HPV 18 was more frequent in adenocarcinomas and adenosquamous carcinomas (86%) than in squamous cell carcinomas (15.8%) (P = 0.0002).
CONCLUSIONS: The combination of L1 general primers and E7 type-specific primers can be of use in detecting HPV DNA in archival tissues. The present study showed a high frequency of multiple HPV infections in cervical carcinomas. Hence, relevant HPV typing information in cervical carcinoma is very important for further HPV vaccine design and application.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018855     DOI: 10.1016/S1386-6532(03)00167-7

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  14 in total

1.  Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas.

Authors:  Irene Kraus; Tor Molden; Ruth Holm; A Kathrine Lie; Frank Karlsen; Gunnar B Kristensen; Hanne Skomedal
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

2.  Prevalence of human papillomavirus in archival samples obtained from patients with cervical pre-malignant and malignant lesions from Northeast Brazil.

Authors:  José V Fernandes; Rosely V Meissner; Maria Gf Carvalho; Thales Aam Fernandes; Paulo Rm Azevedo; João S Sobrinho; José Cm Prado; Luisa L Villa
Journal:  BMC Res Notes       Date:  2010-04-08

3.  Cervical HPV infection in Romanian women infected with HIV during early childhood.

Authors:  Luminita Ene; Cristina Voinea; Claudia Stefanescu; Diana Sima; Dan Duiculescu; Sanjay R Mehta
Journal:  Int J STD AIDS       Date:  2015-09-24       Impact factor: 1.359

4.  Decreased p21 expression in HPV-18 positive cervical carcinomas.

Authors:  Lee-Wen Huang; Kok-Min Seow; Chin-Cheng Lee; Yu-Hung Lin; Hun-Shan Pan; Heng-Ju Chen
Journal:  Pathol Oncol Res       Date:  2009-08-06       Impact factor: 3.201

5.  Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma.

Authors:  Ming Guo; Yun Gong; Michael Deavers; Elvio G Silva; Yee Jee Jan; David E Cogdell; Rajyalashmi Luthra; E Lin; Hung Cheng Lai; Wei Zhang; Nour Sneige
Journal:  J Clin Microbiol       Date:  2007-10-31       Impact factor: 5.948

6.  Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial.

Authors:  Ana M Solares; Idania Baladron; Thelvia Ramos; Carmen Valenzuela; Zaida Borbon; Sonia Fanjull; Leonardo Gonzalez; Dagnelia Castillo; Julio Esmir; Milaid Granadillo; Aileen Batte; Alberto Cintado; Mayte Ale; Maria E Fernandez de Cossio; Annia Ferrer; Isis Torrens; Pedro Lopez-Saura
Journal:  ISRN Obstet Gynecol       Date:  2011-03-24

7.  Prevalence of DNA-HPV in male sexual partners of HPV-infected women and concordance of viral types in infected couples.

Authors:  Maria Gabrielle de Lima Rocha; Fabio Lopes Faria; Leonor Gonçalves; Maria do Carmo M Souza; Paula Ávila Fernandes; Ana Paula Fernandes
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

8.  Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.

Authors:  Ana M Solares; Agueda Santana; Idania Baladrón; Carmen Valenzuela; Carlos A González; Alina Díaz; Dagnelia Castillo; Thelvia Ramos; Roberto Gómez; Daniel F Alonso; Luis Herrera; Hugo Sigman; Silvio E Perea; Boris E Acevedo; Pedro López-Saura
Journal:  BMC Cancer       Date:  2009-05-13       Impact factor: 4.430

9.  Serum antibody response to Human papillomavirus (HPV) infections detected by a novel ELISA technique based on denatured recombinant HPV16 L1, L2, E4, E6 and E7 proteins.

Authors:  Paola Di Bonito; Felicia Grasso; Stefania Mochi; Luisa Accardi; Maria Gabriella Donà; Margherita Branca; Silvano Costa; Luciano Mariani; Alberto Agarossi; Marco Ciotti; Kari Syrjänen; Colomba Giorgi
Journal:  Infect Agent Cancer       Date:  2006-11-08       Impact factor: 2.965

10.  Human Papillomavirus type distribution in invasive cervical cancer in Uganda.

Authors:  Michael Odida; Silvia de Sanjosé; Wim Quint; Xavier F Bosch; Joellen Klaustermeier; Elisabete Weiderpass
Journal:  BMC Infect Dis       Date:  2008-06-24       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.